GFP/Luc Reporter Cell Line - A-673

The A-673 cell line is a highly characterized human model of Ewing sarcoma, originally derived from a primary muscle lesion of a 15-year-old female patient. It is extensively utilized in pediatric oncology research because it faithfully retains the pathognomonic EWS-FLI1 chromosomal translocation [t(11;22)(q24;q12)], which is the primary genetic driver of the disease's aggressive pathogenesis. The GFP/Luc Reporter Cell Line - A-673 is a sophisticated, stably transfected derivative explicitly engineered to simultaneously co-express both Green Fluorescent Protein (GFP) and firefly luciferase (Luc). This robust dual-labeling construct ensures continuous, high-level expression of both functional reporter genes across sequential in vitro passages. Crucially, this stable genetic integration is achieved without compromising the fundamental morphological characteristics, the unique molecular profile, or the intrinsic tumorigenic capacity of the original parental A-673 cells.

The incorporation of this dual-reporter system significantly broadens the experimental utility of the A-673 model for translational sarcoma research. For in vitro studies, the distinct GFP expression allows researchers to easily visualize cellular dynamics, quantify rapid proliferation rates, and isolate specific cellular subpopulations using standard fluorescence microscopy and flow cytometry techniques. For in vivo applications, the robust luciferase activity serves as the optimal foundation for non-invasive, longitudinal tracking of tumor progression and metastatic dissemination through bioluminescence imaging (BLI). Because it is a human-derived cell line, the A-673-GFP/Luc model is typically engrafted into immunocompromised mice (such as athymic nude or NSG models) to establish highly aggressive subcutaneous or orthotopic bone xenografts. This specialized reporter line is an exceptionally valuable platform for evaluating the in vivo therapeutic efficacy of targeted pharmacological agents, novel small molecule inhibitors directed at the EWS-FLI1 oncoprotein, and emerging biotherapeutics, facilitating the real-time quantification of localized tumor burden in living subjects.